212 related articles for article (PubMed ID: 23987158)
1. Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy.
Bivalacqua TJ; Pierorazio PM; Gorin MA; Allaf ME; Carter HB; Walsh PC
Urology; 2013 Sep; 82(3):653-8. PubMed ID: 23987158
[TBL] [Abstract][Full Text] [Related]
2. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520
[TBL] [Abstract][Full Text] [Related]
3. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial.
Lestingi JFP; Guglielmetti GB; Trinh QD; Coelho RF; Pontes J; Bastos DA; Cordeiro MD; Sarkis AS; Faraj SF; Mitre AI; Srougi M; Nahas WC
Eur Urol; 2021 May; 79(5):595-604. PubMed ID: 33293077
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence-supported lymphography and extended pelvic lymph node dissection in robot-assisted radical prostatectomy: a prospective, randomized trial.
Harke NN; Godes M; Wagner C; Addali M; Fangmeyer B; Urbanova K; Hadaschik B; Witt JH
World J Urol; 2018 Nov; 36(11):1817-1823. PubMed ID: 29767326
[TBL] [Abstract][Full Text] [Related]
5. Undetectable PSA after radical prostatectomy is more likely in low burden N+ prostate cancer patients when an extended lymph node dissection is performed.
Ramírez-Backhaus M; Mir Maresma MC; Mascarós JM; Bertolo R; Hernández J; Gómez Ferrer A; Casanova-Ramón Borja J; Domínguez Escrig JL; Collado-Serra A; Calatrava Fons A; Rubio-Briones J
Actas Urol Esp (Engl Ed); 2019 Nov; 43(9):480-487. PubMed ID: 31174878
[TBL] [Abstract][Full Text] [Related]
6. Extended versus limited pelvic lymph node dissection during bilateral nerve-sparing radical prostatectomy and its effect on continence and erectile function recovery: long-term results and trifecta rates of a comparative analysis.
Hatzichristodoulou G; Wagenpfeil S; Wagenpfeil G; Maurer T; Horn T; Herkommer K; Hegemann M; Gschwend JE; Kübler H
World J Urol; 2016 Jun; 34(6):811-20. PubMed ID: 26420596
[TBL] [Abstract][Full Text] [Related]
7. Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques.
Yaxley JW; Dagher J; Delahunt B; Egevad L; Srigley J; Samaratunga H
World J Urol; 2018 Jan; 36(1):15-20. PubMed ID: 29116393
[TBL] [Abstract][Full Text] [Related]
8. Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection.
Altok M; Babaian K; Achim MF; Achim GC; Troncoso P; Matin SF; Chapin BF; Davis JW
BJU Int; 2018 Jul; 122(1):66-75. PubMed ID: 29446205
[TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
10. Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
Preisser F; van den Bergh RCN; Gandaglia G; Ost P; Surcel CI; Sooriakumaran P; Montorsi F; Graefen M; van der Poel H; de la Taille A; Briganti A; Salomon L; Ploussard G; Tilki D;
J Urol; 2020 Feb; 203(2):338-343. PubMed ID: 31437119
[TBL] [Abstract][Full Text] [Related]
11. Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis.
Wettstein MS; David LA; Pazhepurackel C; Qureshi AA; Zisman A; Nesbitt M; Saba K; Herrera-Caceres JO; Fankhauser CD; Ahmad A; Hamilton RJ; Eberli D; Zlotta AR; Sulser T; Fleshner NE; Poyet C; Finelli A; Hermanns T; Kulkarni GS
Prostate; 2021 Apr; 81(5):286-294. PubMed ID: 33599318
[TBL] [Abstract][Full Text] [Related]
12. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
[TBL] [Abstract][Full Text] [Related]
13. Pelvic lymph node dissection in prostate cancer.
Briganti A; Blute ML; Eastham JH; Graefen M; Heidenreich A; Karnes JR; Montorsi F; Studer UE
Eur Urol; 2009 Jun; 55(6):1251-65. PubMed ID: 19297079
[TBL] [Abstract][Full Text] [Related]
14. Association between Lymph Node Counts and Oncological Outcomes in Lymph Node Positive Prostate Cancer.
Mandel P; Kriegmair MC; Bogdan K; Boehm K; Budäus L; Graefen M; Huland H; Tilki D
Eur Urol Focus; 2017 Apr; 3(2-3):248-255. PubMed ID: 28753755
[TBL] [Abstract][Full Text] [Related]
15. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
[TBL] [Abstract][Full Text] [Related]
16. Extended pelvic lymphadenectomy for prostate cancer: will the previously reported benefits be reproduced in hospitals with lower surgical volumes?
Lindberg C; Davidsson T; Gudjónsson S; Hilmarsson R; Liedberg F; Bratt O
Scand J Urol Nephrol; 2009; 43(6):437-41. PubMed ID: 19707953
[TBL] [Abstract][Full Text] [Related]
17. Extended versus standard pelvic lymphadenectomy during robot-assisted radical prostatectomy: the role of extended template as an independent predictor of lymph node invasion with comparable morbidity burden.
Mistretta FA; Boeri L; Grasso AA; Lo Russo V; Albo G; DE Lorenzis E; Maggioni M; Palmisano F; Dell'orto P; Bosari S; Rocco B
Minerva Urol Nefrol; 2017 Oct; 69(5):475-485. PubMed ID: 28281741
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Adding Sentinel Node Biopsy to Extended Pelvic Lymph Node Dissection on Biochemical Recurrence in Prostate Cancer Patients Treated with Robot-Assisted Radical Prostatectomy.
Grivas N; Wit EMK; Kuusk T; KleinJan GH; Donswijk ML; van Leeuwen FWB; van der Poel HG
J Nucl Med; 2018 Feb; 59(2):204-209. PubMed ID: 28747519
[TBL] [Abstract][Full Text] [Related]
19. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.
Briganti A; Karnes JR; Da Pozzo LF; Cozzarini C; Gallina A; Suardi N; Bianchi M; Freschi M; Doglioni C; Fazio F; Rigatti P; Montorsi F; Blute ML
Eur Urol; 2009 Feb; 55(2):261-70. PubMed ID: 18838212
[TBL] [Abstract][Full Text] [Related]
20. Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.
Mandel P; Rosenbaum C; Pompe RS; Steuber T; Salomon G; Chun FK; Graefen M; Huland H; Tilki D
World J Urol; 2017 Dec; 35(12):1833-1839. PubMed ID: 28828530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
